Alteration of Gut Microbiome in Patients With Schizophrenia Indicates Links Between Bacterial Tyrosine Biosynthesis and Cognitive Dysfunction.
Case-control study
Cognition
Gut microbiome
Metagenomics
Schizophrenia
Tyrosine biosynthesis
Journal
Biological psychiatry global open science
ISSN: 2667-1743
Titre abrégé: Biol Psychiatry Glob Open Sci
Pays: United States
ID NLM: 9918227369306676
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
02
11
2021
revised:
28
01
2022
accepted:
29
01
2022
medline:
10
2
2022
pubmed:
10
2
2022
entrez:
1
5
2023
Statut:
epublish
Résumé
Schizophrenia (SCZ) is a heterogeneous neuropsychiatric disorder for which current treatment has insufficient efficacy and severe adverse effects. The modifiable gut microbiome might be a potential target for intervention to improve neurobiological functions through the gut-microbiome-brain axis. In this case-control study, gut microbiota of 132 patients with SCZ and increased waist circumference were compared with gut microbiota of two age- and sex-matched control groups, composed of 132 healthy individuals and 132 individuals with metabolic syndrome. Shotgun sequencing was used to characterize fecal samples at the taxonomic and functional levels. Cognition of the patients with SCZ was evaluated using the Brief Assessment of Cognition instrument. SCZ gut microbiota differed significantly from those of healthy control subjects and individuals with metabolic syndrome in terms of richness and global composition. SCZ gut microbiota were notably enriched in Overall, this study shows that the gut microbiome of patients with SCZ differs greatly from that of healthy control subjects or individuals with metabolic syndrome. Cognitive function of patients with SCZ is associated with the potential for gut bacterial biosynthesis of tyrosine, a precursor for dopamine, suggesting that gut microbiota might be an intervention target for alleviation of cognitive dysfunction in SCZ.
Sections du résumé
Background
UNASSIGNED
Schizophrenia (SCZ) is a heterogeneous neuropsychiatric disorder for which current treatment has insufficient efficacy and severe adverse effects. The modifiable gut microbiome might be a potential target for intervention to improve neurobiological functions through the gut-microbiome-brain axis.
Methods
UNASSIGNED
In this case-control study, gut microbiota of 132 patients with SCZ and increased waist circumference were compared with gut microbiota of two age- and sex-matched control groups, composed of 132 healthy individuals and 132 individuals with metabolic syndrome. Shotgun sequencing was used to characterize fecal samples at the taxonomic and functional levels. Cognition of the patients with SCZ was evaluated using the Brief Assessment of Cognition instrument.
Results
UNASSIGNED
SCZ gut microbiota differed significantly from those of healthy control subjects and individuals with metabolic syndrome in terms of richness and global composition. SCZ gut microbiota were notably enriched in
Conclusions
UNASSIGNED
Overall, this study shows that the gut microbiome of patients with SCZ differs greatly from that of healthy control subjects or individuals with metabolic syndrome. Cognitive function of patients with SCZ is associated with the potential for gut bacterial biosynthesis of tyrosine, a precursor for dopamine, suggesting that gut microbiota might be an intervention target for alleviation of cognitive dysfunction in SCZ.
Identifiants
pubmed: 37124355
doi: 10.1016/j.bpsgos.2022.01.009
pii: S2667-1743(22)00014-3
pmc: PMC10140391
doi:
Types de publication
Journal Article
Langues
eng
Pagination
283-291Informations de copyright
© 2022 The Authors.
Références
Genes Nutr. 2011 Aug;6(3):209-40
pubmed: 21617937
Front Cell Neurosci. 2017 Mar 03;11:46
pubmed: 28316565
Front Neurosci. 2015 Oct 21;9:372
pubmed: 26539073
Mol Psychiatry. 2021 Aug;26(8):4158-4178
pubmed: 33230205
J Psychiatr Res. 2015 Nov;70:50-7
pubmed: 26424423
Schizophr Res. 2018 Jul;197:470-477
pubmed: 29352709
Mol Psychiatry. 2016 Jun;21(6):786-96
pubmed: 27067014
World Psychiatry. 2016 Jun;15(2):155-65
pubmed: 27265706
Behav Brain Res. 2020 Feb 3;379:112374
pubmed: 31759045
Int J Neuropsychopharmacol. 2019 Jan 1;22(1):37-52
pubmed: 30099552
Schizophr Res. 2018 Nov;201:299-306
pubmed: 29859859
Neuroreport. 2018 Mar 21;29(5):417-425
pubmed: 29432299
Nat Genet. 2013 Sep;45(9):984-94
pubmed: 23933821
Schizophr Res. 2019 Feb;204:23-29
pubmed: 30268819
Schizophr Res. 2004 Jun 1;68(2-3):283-97
pubmed: 15099610
Bipolar Disord. 2019 Feb;21(1):40-49
pubmed: 30051546
JAMA Psychiatry. 2021 Dec 1;78(12):1343-1354
pubmed: 34524405
Schizophr Res. 2021 Aug;234:1-10
pubmed: 31952911
Transl Psychiatry. 2019 Sep 18;9(1):233
pubmed: 31534116
PLoS One. 2014 Dec 15;9(12):e115225
pubmed: 25506936
Schizophr Res. 2018 Feb;192:398-403
pubmed: 28442250
Int J Neuropsychopharmacol. 2006 Apr;9(2):247-55
pubmed: 15972118
Curr Psychiatry Rep. 2015 May;17(5):27
pubmed: 25773227
Brain Behav Immun. 2020 Mar;85:120-127
pubmed: 31255682
Mod Probl Pharmacopsychiatry. 1990;24:73-88
pubmed: 2336066
J Mol Psychiatry. 2014 Jun 27;2(1):4
pubmed: 25408914
Sci Adv. 2019 Feb 06;5(2):eaau8317
pubmed: 30775438
PeerJ. 2020 Jul 29;8:e9574
pubmed: 32821537
Mol Psychiatry. 2020 Nov;25(11):2905-2918
pubmed: 31391545
Nature. 2013 Aug 29;500(7464):541-6
pubmed: 23985870
Clin Epidemiol. 2017 Feb 23;9:127-139
pubmed: 28275316
Psychiatry Res. 2020 Sep;291:113260
pubmed: 32763534
Lancet. 2009 Aug 22;374(9690):635-45
pubmed: 19700006
Genome Biol. 2017 Jul 27;18(1):142
pubmed: 28750650
Nat Commun. 2020 Mar 31;11(1):1612
pubmed: 32235826
BMC Med. 2016 Apr 19;14:58
pubmed: 27090095
Nat Rev Microbiol. 2018 Jul;16(7):410-422
pubmed: 29795328
Compr Psychiatry. 2007 Jan-Feb;48(1):88-94
pubmed: 17145287
J Psychiatr Res. 2020 Apr;123:136-144
pubmed: 32065949